Preeclampsia Through an Endocrine and Metabolic Lens

Preeclampsia represents more than a blood pressure disorder of pregnancy. It reflects a complex endocrine and metabolic stress response that unfolds across the placenta, vasculature, kidneys, and maternal hormonal systems.

Clinically, we define preeclampsia as new-onset hypertension after 20 weeks of gestation — blood pressure ≥140/90 mmHg — with proteinuria ≥300 mg per 24 hours, a urine protein-to-creatinine ratio of 0.3 or higher, or evidence of organ dysfunction. Severe features include pressures ≥160/110 mmHg, thrombocytopenia, rising creatinine, elevated liver enzymes, or neurologic symptoms.

While these criteria define the syndrome clinically, they do not explain why it develops. To understand the ‘why,’ we must look at the hormonal story behind the numbers. As a specialist in endocrinology, diabetes, and hypertension, I approach preeclampsia as a holistic disorder of vascular biology, metabolic signaling, and placental endocrine function.

The Placenta as an Endocrine Organ

The placenta does not function as passive tissue. It acts as a powerful endocrine organ that secretes:

• Human placental lactogen
• Progesterone and estrogens
• Corticotropin-releasing-hormone
• Angiogenic and anti-angiogenic factors

In normal pregnancy, placental signals promote vasodilation, plasma volume expansion of nearly 40–50%, and adaptive insulin resistance that supports fetal growth.

In preeclampsia, placental implantation remains shallow. Spiral arteries fail to remodel properly. Reduced placental perfusion triggers oxidative stress and release of anti-angiogenic mediators such as soluble fms-like tyrosine kinase 1, sFlt-1, and soluble endoglin.

These factors antagonize vascular endothelial growth factor and placental growth factor. Endothelial dysfunction follows. The result manifests as hypertension, capillary leak, and multi-organ stress.

Insulin Resistance and Metabolic Terrain

Pregnancy normally induces progressive insulin resistance, especially in the third trimester. In women with underlying metabolic stress, that adaptive shift can tip into maladaptation. Women who develop preeclampsia more commonly exhibit:

• Higher pre-pregnancy BMI
• Fasting glucose in the 95–105 mg/dL range
• Elevated triglycerides often >150 mg/dL
• Low HDL cholesterol
• Subtle elevations in fasting insulin

These patterns overlap with early metabolic syndrome. Preeclampsia often reveals preexisting metabolic vulnerability rather than creating it de novo.

In fact, women with gestational diabetes carry roughly a 2 fold increased risk of preeclampsia. Obesity increases risk 2 to 4 fold depending on severity.

This intersection underscores a broader truth. Hormones, adipose tissue signaling, insulin dynamics, and vascular tone all interact.

The Renin–Angiotensin–Aldosterone System

The renin–angiotensin–aldosterone system, RAAS, normally upregulates during pregnancy. Plasma renin activity and aldosterone rise substantially, yet blood pressure remains controlled because vascular sensitivity decreases.

In preeclampsia, vascular sensitivity to angiotensin II increases paradoxically. Circulating renin and aldosterone often become suppressed compared to normal pregnancy. Endothelial dysfunction amplifies vasoconstriction. This endocrine shift contributes to:

• Elevated systemic vascular resistance
• Reduced renal perfusion
• Proteinuria from glomerular endotheliosis

The hormonal balance that once supported pregnancy becomes maladaptive.

Cortisol, Sympathetic Tone, and Stress Biology

Pregnancy raises cortisol levels progressively. The placenta also produces corticotropin-releasing-hormone (CRH), which further stimulates maternal cortisol production.

In preeclampsia, exaggerated stress signaling and heightened sympathetic tone may amplify vascular constriction. Heart rate variability often decreases. Blood pressure variability increases.

As noted in other metabolic conditions, sympathetic activation rarely acts alone. It interacts with insulin resistance, endothelial dysfunction, and inflammatory signaling.

Lipids and Vascular Injury

Normal pregnancy increases triglycerides by 2 to 3 fold. In women who develop preeclampsia, triglycerides often rise more sharply, while HDL falls.

Elevated triglyceride-rich lipoproteins may contribute to endothelial injury. Oxidized lipids promote inflammatory cascades within placental and maternal vessels.

A balanced viewpoint recognizes that lipid shifts in pregnancy remain physiologic. Yet exaggerated responses may signal vulnerability.

Long-Term Cardiometabolic Implications

Preeclampsia does not end at delivery. Women with prior preeclampsia face:

• HTN — Approximately 2 fold higher lifetime risk of hypertension
• CVD — 2 fold increased risk of ischemic heart disease
• DM2 — Higher rates of type 2 diabetes
• CKD — Increased risk of chronic kidney disease

Women with early onset or severe preeclampsia may face up to a 4-fold higher risk of developing chronic hypertension within 10–15 years.

Preeclampsia functions as an early stress test. It reveals a trajectory that deserves long-term metabolic follow-up.

This concept aligns with trajectory medicine rather than threshold medicine. A single elevated pressure matters less than the direction of vascular biology over decades.

Clinical Approach in an Endocrine Practice

In my practice, evaluation extends beyond acute obstetric management. We consider:

• Pre-pregnancy metabolic status
• Weight trajectory and body composition
• Fasting glucose, insulin, and lipid profile
• Blood pressure patterns including ambulatory monitoring
• Sleep quality and sympathetic tone

During pregnancy, collaboration with obstetrics remains essential. After pregnancy, structured follow-up becomes equally important.

Prevention Strategies Before and Between Pregnancies

Evidence supports several meaningful interventions:

• Weight optimization before conception
• Regular resistance and aerobic exercise
• Mediterranean-style nutrition
• Tight glucose control in gestational diabetes
• Low-dose aspirin starting late in the first trimester for selected high-risk women

In high-risk metabolic profiles, early optimization before conception often matters more than late intervention during pregnancy.

Even 5—10% weight reduction before pregnancy can lower inflammatory and insulin resistant burden.

Patient Case Variations

• Case 1 — Metabolic Predisposition: A 32-year-old woman with BMI 33 enters pregnancy with triglycerides 185 mg/dL and fasting glucose 102 mg/dL. At 30 weeks, blood pressure rises to 148/92 mmHg with proteinuria 400 mg. Postpartum evaluation confirms persistent insulin resistance. Structured metabolic intervention reduces her long-term risk trajectory.
• Case 2 — Lean but Insulin Resistant: A 29-year-old woman with normal BMI develops gestational diabetes requiring insulin. At 34 weeks, she develops pressures 150/96 mmHg. Postpartum labs reveal elevated fasting insulin despite normal weight. Body composition analysis shows low muscle mass. Resistance training improves metabolic resilience before her second pregnancy.
• Case 3 — Severe Early Onset: A 38-year-old woman develops severe preeclampsia at 28 weeks with pressures 168/110 mmHg and rising creatinine. Delivery occurs preterm. Long-term follow-up reveals persistent hypertension requiring treatment. Early cardiovascular prevention begins within 6 months postpartum.
• Case 4 — Postpartum Recognition: A 35-year-old woman presents 10 days after delivery with headaches and blood pressure 162/104 mmHg. She receives acute management. Two years later, ambulatory monitoring shows masked hypertension. Ongoing endocrine follow-up prevents silent progression.
• Case 5 — Prevention Success: A 34-year-old woman with prior preeclampsia adopts structured weight reduction of 8%, improves triglycerides from 210 to 120 mg/dL, and strengthens insulin sensitivity before her second pregnancy. She completes pregnancy without hypertensive complications.

Summary Table

Domain	Normal Pregnancy	Preeclampsia
Placental Invasion	Deep remodeling	Shallow remodeling
Angiogenic Balance	VEGF supported	sFlt-1 dominant
Insulin Resistance	Physiologic	Exaggerated
RAAS Sensitivity	Reduced vascular response	Increased response
Long-Term Risk	Baseline	Elevated cardiometabolic risk

The Broader Context

Preeclampsia highlights the intersection of endocrinology, metabolism, vascular biology, and long-term prevention. It reminds us that pregnancy does not exist outside cardiometabolic health. Instead, it amplifies underlying physiology.

A meaningful approach avoids extremes. We neither dismiss preeclampsia as isolated obstetric history nor medicalize every pregnancy as pathology. We examine patterns, identify terrain, and intervene thoughtfully.

At our practice in Montgomery County, Maryland, and through virtual care, we view preeclampsia within a broader metabolic and endocrine framework. We provide personalized, comprehensive follow-up that addresses insulin resistance, lipid health, blood pressure regulation, and long-term cardiovascular prevention with a smart, balanced strategy.